Racura Oncology Ltd
Racura Oncology Advances CPACS Trial to Next Dose Level
Racura Oncology advances RC220 CPACS trial to 80mg/m2 as SRC clears Cohort 2; updated cardioprotection protocol; A$19.38m cash runway to CY2027.
Racura Oncology Advances Lung Cancer Program with HARNESS-1 Trial Approval
Racura Oncology wins HARNESS-1 Phase 1a/b governance approval for RC220/osimertinib in EGFR-mutant NSCLC, enabling site initiation and recruitment.
Race Oncology Identifies Breakthrough Anticancer Mechanism for Bisantrene (RCDS1)
Race Oncology (ASX: RAC) has discovered the primary anticancer mechanism of action for its lead drug candidate (E,E)-bisantrene, also known as RCDS1. New studies show the compound acts by binding to special DNA and RNA structures called G-quadruplexes, or G4s, which regulate many cancer-driving genes including the master switch MYC. Chief executive officer Dr Daniel Tillett […]
Race Oncology’s bisantrene RC220 AML treatment earns coveted FDA orphan drug designation
Race Oncology (ASX: RAC) has achieved a significant breakthrough with the US Food and Drug Administration (FDA) awarding orphan drug designation (ODD) to the company’s acute myeloid leukemia (AML) candidate bisantrene RC220. The coveted designation qualifies Race for various benefits including tax credits, fee exemptions, market exclusivity and regulatory assistance from the FDA throughout the […]